Studying a blood marker in scleroderma patients with or without lung disease
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at a substance in the blood called CD25 in people who have systemic sclerosis (scleroderma). Some of these people also have interstitial lung disease (ILD), a type of lung scarring. The goal is to see if CD25 levels are different in those with lung disease, which might help doctors understand and track this complication better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult, age 18 or older.
- You have been diagnosed with systemic sclerosis (also called scleroderma) based on standard medical criteria.
- You do not have any other autoimmune disease (like lupus or rheumatoid arthritis).
- If you have interstitial lung disease (ILD), it must be caused by your scleroderma, not by another condition.
- You are willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
This study follows people with systemic sclerosis who also have lung scarring (interstitial lung disease). It aims to map how lung function and lung images change over time, which may help doctors predict and better manage disease progression.
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Hear when a new Assessment of Serum Level of SCD25 in RA, SSc (with or Without ILD) and IPF and Its Correlation with Disease Activity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.